Robbins LLP Advocates for Shareholder Rights in ADMA Biologics Class Action Lawsuit

On June 12, 2026, Robbins LLP, a law firm known for its commitment to shareholder rights, announced the initiation of a class action lawsuit aimed at ADMA Biologics, Inc. This action targets all investors who bought or otherwise acquired securities of ADMA Biologics, a biopharmaceutical company listed on NASDAQ under the symbol ADMA, during the period ranging from August 9, 2024, to March 25, 2026. The firm is reaching out to stockholders who may have suffered losses or were misled regarding the company's financial performance and business practices.

ADMA Biologics specializes in developing, manufacturing, and marketing plasma-derived biologics, targeting treatments for immune deficiencies and infectious diseases both in the United States and internationally. However, the lawsuit sheds light on serious allegations surrounding the company's lack of transparency and possible misconduct.

Allegations in the Lawsuit

According to the filed complaint, Robbins LLP is examining allegations that ADMA Biologics misled investors concerning its operations and financial condition. Key points emerging from the complaint include allegations that ADMA engaged in questionable practices that negatively impacted shareholder confidence and compromised trust. Specifically, the accusations state that:
1. ADMA Biologics failed to disclose a material related party transaction that could have affected its financial stability.
2. The company allegedly employed a method known as channel stuffing, a deceptive practice used to inflate revenue figures artificially.
3. There were claims of inadequate internal controls within the company, raising questions about its business operations.
4. As a result of these issues, the statements made by ADMA regarding its business prospects were misleading or lacked a reasonable basis.

Impact on Stock Prices

On March 24, 2026, a report issued by Culper Research titled "ADMA Biologics Inc (ADMA) Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported" catalyzed a significant decline in ADMA stock value. The report disclosed that the company’s alleged growth was propelled not by legitimate financial health, but by manipulative practices, including channel stuffing and undisclosed alliances with distribution partners. Following this revelation, ADMA's stock plummeted by $2.26 per share, reflecting a 16.6% decrease, closing at $11.33. The fallout continued into the next trading day, where the stock dropped further by $1.70, marking a total decrease of 15.0%.

What This Means for Shareholders

Affected shareholders may wish to consider participating in the class action lawsuit against ADMA Biologics, Inc. Those interested in serving as a lead plaintiff—the representative figure in a class action case—are encouraged to reach out to Robbins LLP. The lead plaintiff's role is vital, as they will direct the litigation on behalf of fellow class members. Importantly, shareholders are under no obligation to actively participate in the case to be eligible for recovery if the class action succeeds. For individuals who prefer a passive role, they remain 'absent class members' and can still receive potential benefits from the lawsuit outcomes.

Robbins LLP operates on a contingency fee basis, meaning shareholders will not incur any upfront costs during the legal process. This approach is in line with the firm's dedication to making justice accessible, ensuring that claimants can pursue their rights without financial burden.

About Robbins LLP

Founded in 2002, Robbins LLP has established itself as a leader in shareholder rights litigation. The firm's dedicated team of attorneys is committed to supporting investors in recovering losses, enforcing corporate governance improvements, and holding company executives accountable for their actions. They work tirelessly to ensure that shareholders' voices are heard and that their rights are preserved.

To stay updated on the developments of the ADMA Biologics class action or to receive notifications about future corporate accountability initiatives, interested parties are encouraged to sign up for Stock Watch.

For further information, please contact Robbins LLP at 800-350-6003 or submit an inquiry via their website.